FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Ty | pe Response | s) | | | | | | | | | | | | | |
|---|---|--|--|--|-------------------------|--|-----------------------|--|---|--|--|--|---|---------------------------------------|-------------|
| 1. Name and Address of Reporting Person* MANZO MICHAEL P. | | | | 2. Issuer Name and Ticker or Trading Symbol EYEGATE PHARMACEUTICALS INC [EYEG] | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below) VP of Engineering | | | | | |
| (Last) (First) (Middle) C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108 | | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/07/2020 | | | | | | | | V. | P of Enginee | ring | |
| (Street) WALTHAM, MA 02452 | | | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person | | | | | |
| (City |) | (State) | (Zip) | Table I - Non-Derivative Securities Acqui | | | | | | uired, Disp | ired, Disposed of, or Beneficially Owned | | | | |
| 1.Title of Security (Instr. 3) | | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, any (Month/Day/Yes | if Co- (In: | | (Instr. 3, 4 and 5) (A) or | | of (D) | Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| Common | Common Stock 12 | | 12/07/2020 | | I | F ⁽¹⁾ 91 D \$ 3.76 | | | 17,407 | | | D | | | |
| Reminder: | Report on a s | separate line fo | | Derivative Secur | ities A | cquire | Pers cont the f | ons what ained in the contract of the contract | no responding this for splays a | orm ar curre | e not requently valid | OMB con | formation spond unle trol numbe | ss | 1474 (9-02) |
| Security | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/ | 3A. Deemed Execution Da any | 4. Transaction Code (Instr. 8) | 5. Num of Deri | vative rities uired or osed O) r. 3, | | | 7. T Am Und Sec (Ins 4) | Title and 8. Price of | | 9. Number Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4) | Owners Form of Derivati Security Direct (or Indire | Beneficial Ownership (Instr. 4) | |

Reporting Owners

| | Relationships | | | | | | |
|---|---------------|--------------|-------------------|-------|--|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | | |
| MANZO MICHAEL P. C/O EYEGATE PHARMACEUTICALS, INC. 271 WAVERLEY OAKS ROAD, SUITE 108 WALTHAM, MA 02452 | | | VP of Engineering | | | | |

Signatures

| /s/ Sarah Romano, Attorney-in-Fact* | 12/08/2020 | | |
|-------------------------------------|------------|--|--|
| **Signature of Reporting Person | Date | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Sale of shares to cover taxes due on restricted stock that vested on 12/01/2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.